Lifeward Ltd. LFWD
NASDAQ · United States · Health Technology
$5.85-0.25 (-4.10%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website. The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, levera
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.